Cargando…

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment

Intrinsic and acquired resistance to current HER2 targeted therapies remains a challenge in clinics. We have developed a therapeutic HER2 siRNA delivered using mesoporous silica nanoparticles modified with polymers and conjugated with HER2 targeting antibodies. Our previous studies have shown that o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Shenda, Ngamcherdtrakul, Worapol, Reda, Moataz, Hu, Zhi, Gray, Joe W., Yantasee, Wassana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991725/ https://www.ncbi.nlm.nih.gov/pubmed/29879129 http://dx.doi.org/10.1371/journal.pone.0198141

Ejemplares similares

Therapeutic siRNA for drug-resistant HER2-positive breast cancer
por: Gu, Shenda, et al.
Publicado: (2016)

Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery
por: Ngamcherdtrakul, Worapol, et al.
Publicado: (2018)

Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis
por: Ngamcherdtrakul, Worapol, et al.
Publicado: (2019)

Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles
por: Morry, Jingga, et al.
Publicado: (2016)

Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model
por: Ngamcherdtrakul, Worapol, et al.
Publicado: (2019)

Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
por: Reda, Moataz, et al.
Publicado: (2022)

Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
por: Draz, Mohamed Shehata, et al.
Publicado: (2014)

Novel Oral Detoxification of Mercury, Cadmium, And Lead with Thiol-Modified Nanoporous Silica
por: Sangvanich, Thanapon, et al.
Publicado: (2014)

Correction to Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Nanoporous Silica
por: Sangvanich, Thanapon, et al.
Publicado: (2014)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer
por: Yu, Xiaolin, et al.
Publicado: (2017)

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
por: Palanca-Wessels, Maria C., et al.
Publicado: (2016)

Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment
por: Eljack, Sahar, et al.
Publicado: (2022)

Delivery of chemo-sensitizing siRNAs to HER2(+)-breast cancer cells using RNA aptamers
por: Thiel, Kristina W., et al.
Publicado: (2012)

The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell
por: Liu, Kun, et al.
Publicado: (2013)

Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras
por: Nachreiner, Inga, et al.
Publicado: (2019)

Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division
por: Akimov, I.A., et al.
Publicado: (2011)

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth
por: Lu, Yuan, et al.
Publicado: (2016)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells
por: Yuan, Heng-Heng, et al.
Publicado: (2017)

Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
por: Wang, Xiaoli, et al.
Publicado: (2018)

Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells
por: Khan, Arif, et al.
Publicado: (2020)

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells
por: Eljack, Sahar, et al.
Publicado: (2022)

Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA
por: Yingyuad, Peerada, et al.
Publicado: (2014)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
por: Watson, Spencer S., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
por: Serra, V, et al.
Publicado: (2011)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
por: Yamaguchi, Haruka, et al.
Publicado: (2018)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ujogdovcugjfedssaemuh2h803